Compare H2O America (HTO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs State Street SPDR S&P Biotech ETF — how do they compare? H2O America trades at $61.79 (market cap $2.62B), while State Street SPDR S&P Biotech ETF trades at $159.58. The key difference: H2O America pays a 2.81% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, H2O America nearer its low. Which is the better fit depends on your goals.
| HTO | XBI | |
|---|---|---|
Market Cap | $2.62B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $65.43 | $164.28 |
52-Week Low | $44.44 | $88.79 |
Enterprise Value | $4.41B | — |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.57, up 2.16% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent transformative acquisitions in Texas water utilities drive growth potential, though execution risks and share dilution from equity issuance present challenges. Technical indicators show bullish momentum with key resistance at $63 and support at $61.
Outlook remains positive with 83% analyst buy ratings and $69.50 consensus target offering 11% upside. Dividend sustainability and acquisition integration are key watchpoints. Risks include execution challenges from Quadvest deal and potential EPS dilution from recent 11M share issuance.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
